13 September 2023
Dear Valued Clients,

STEMLIFE IS 21 AND HERE WITH YOU AT EVERY STEP OF THE WAY
I hope this letter finds you in good health. Thank you very much for choosing StemLife as your preferred cord blood bank. I am writing to address the recent closure of a cord blood bank in our industry, which has understandably raised concerns within our cherished community of parents and guardians who have entrusted us with the priceless duty of preserving their child's stem cells. While this cord blood bank is not related with our organisation, we understand that such events can cause uncertainty in our industry.

First and foremost, I want to reassure you that StemLife Berhad ("StemLife" or the “Company”) and our parent company, Cordlife Group Limited ("Cordlife Group” or the “Group”), are financially healthy and well-prepared to keep our promise to safeguard your child's stem cells for the long term. Our financial stability is one of our top priorities, and I would like to share some key information to put your mind at ease:

1. Strong Financial Foundation: We take great pride in our financial stability and have diligently built a solid financial foundation to ensure the long-term viability of our Company and the Group. Cordlife Group had a net cash position of about SGD82.7 million as of 30 June 2023. Our financial reserves are more than sufficient not only to sustain our business but also to ensure the safekeeping and accessibility of your child’s stem cells at all times.
2. Part of Asia's Largest Network of Cord Blood Banks: StemLife is a majority-owned subsidiary of Cordlife Group Limited, which operates the largest network of cord blood banks in Asia with seven facilities in six different markets. Stemlife also has a direct stake in Thailand's largest cord blood bank. These demonstrate our commitment to the business and underscore our dedication to providing the best standards of service.
3. Long-Term Commitment: We became operational in 2002 with a singular mission: to secure the future health of your children by preserving their stem cells. Today, this commitment remains stronger than ever. We are dedicated to continuing our services for many years to come, ensuring that your family can access the life-saving benefits of cell therapy when needed.
4. Publicly Listed Company: As a publicly listed company on the Singapore Exchange, Cordlife Group operates with transparency and accountability. Our financial information, including reports, is readily accessible to the public. We encourage you to explore this information at https://cordlife.listedcompany.com/ to gain a comprehensive understanding of our financial health and stability.

In light of these assurances, we believe that StemLife remains your best choice for stem cell banking. As a part of Asia's largest network of cord blood banks, combined with our unwavering dedication to preserving the health and well-being of your children, we set ourselves apart from the competition. We firmly believe that our fundamentals are not only solid but also focused on ensuring your peace of mind for years to come.

We understand the importance of informed decision-making and are committed to providing you and other expectant parents with all the information necessary to make the best decisions for the family. Should you have any questions, please feel free to reach out to our dedicated customer service team at +603 2779 0033 or info@stemlife.com. We are here to support you every step of the way. If you know of any expectant parents who are considering cord blood banking, please recommend them to StemLife so that we can help them protect their child’s stem cells.

Once again, thank you very much for your continued trust and support. We eagerly look forward to serving you and your family for many years to come.

Yours sincerely,

Zahrein Redza
Chief Operating Officer
StemLife Berhad